In its Beyond Borders 2024 report, issued in tandem with the start of this year’s BIO International Convention, EY analysts said the biopharmaceutical industry appeared to turn a corner in late 2023 with strong dealmaking activity that has continued into 2024, generating optimism that financing for smaller and less established companies will improve.
EY: Buyers Need To Fill Revenue Gaps But M&A Targets May Be Scarce
In its Beyond Borders 2024 report, coinciding with the start of the BIO meeting, EY analysts see declining revenues for big pharma, which could be addressed by M&A, if the right takeouts exist.
